Evidence map›Paper›PMID 36383528›Full record

ArticlePloS one2022

Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study.

Batuhan K Karaman, Elizabeth C Mormino, Mert R Sabuncu, Alzheimer’s Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Multi-Modal Deep Clustering Survival Machines for Alzheimer's Disease Subtype Discovery.... IEEE International Conference on Computer Vision workshops. IEEE International Conference on Computer Vision · 2025
    Article
  7. Knockout: A simple way to handle missing inputs.Transactions on machine learning research · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. A Framework for Interpretability in Machine Learning for Medical Imaging.IEEE access : practical innovations, open solutions · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Batuhan K KaramanSchool of Electrical and Computer Engineering, Cornell University and Cornell Tech, New York, NY, United States of America.ORCID 0000-0002-5108-5417
Elizabeth C MorminoDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States of America.
Mert R SabuncuSchool of Electrical and Computer Engineering, Cornell University and Cornell Tech, New York, NY, United States of America.ORCID 0000-0002-7068-719X
Alzheimer’s Disease Neuroimaging Initiative

Funding

Advanced machine learning algorithms that integrate genomewide, longitudinal MRI and demographic data to predict future cognitive decline toward dementiaR01AG053949 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI SABUNCU, MERT RORY · 2017 to 2021
$2.4M
Novel Bioinformatics Strategies to Study Associations Between Genetic Variants and Neuroanatomical ShapeR01LM012719 · NLM · CORNELL UNIVERSITY · PI SABUNCU, MERT RORY · 2017 to 2020
$1.4M
NIA NIH HHS R01 AG053949NLM NIH HHS R01 LM012719
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition that progresses over decades. Early detection of individuals at high risk of future progression toward AD is likely to be of critical significance for the successful treatment and/or prevention of this devastating disease. In this paper, we present an empirical study to characterize how predictable an individual subjects' future AD trajectory is, several years in advance, based on rich multi-modal data, and using modern deep learning methods. Crucially, the machine learning strategy we propose can handle different future time horizons and can be trained with heterogeneous data that exhibit missingness and non-uniform follow-up visit times. Our experiments demonstrate that our strategy yields predictions that are more accurate than a model trained on a single time horizon (e.g. 3 years), which is common practice in prior literature. We also provide a comparison between linear and nonlinear models, verifying the well-established insight that the latter can offer a boost in performance. Our results also confirm that predicting future decline for cognitively normal (CN) individuals is more challenging than for individuals with mild cognitive impairment (MCI). Intriguingly, however, we discover that prediction accuracy decreases with increasing time horizon for CN subjects, but the trend is in the opposite direction for MCI subjects. Additionally, we quantify the contribution of different data types in prediction, which yields novel insights into the utility of different biomarkers. We find that molecular biomarkers are not as helpful for CN individuals as they are for MCI individuals, whereas magnetic resonance imaging biomarkers (hippocampus volume, specifically) offer a significant boost in prediction accuracy for CN individuals. Finally, we show how our model's prediction reveals the evolution of individual-level progression risk over a five-year time horizon. Our code is available at https://github.com/batuhankmkaraman/mlbasedad.

Indexed as

Alzheimer DiseaseCognitive DysfunctionBiomarkersDisease ProgressionHumansMachine LearningMagnetic Resonance ImagingBiomarkers

Identifiers

PMID36383528
PMCPMC9668188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.